RECENT ADVANCES IN IMMUNOTHERAPY FOR THE TREATMENT OF OVARIAN CANCER
RECENT ADVANCES IN IMMUNOTHERAPY FOR THE TREATMENT OF OVARIAN CANCER

Summary/Abstract: Background: Ovarian cancer remains one of the most lethal gynecologic malignancies, ranking eighth in both incidence and mortality among women. Its asymptomatic early course and nonspecific symptoms often lead to late-stage diagnosis and a poor prognosis. Aim of the study: The aim of this article is to present the current status of immunotherapy in the treatment of ovarian cancer. Material and methods: A narrative review of the available literature was conducted, focusing on recent trials and studies evaluating immunotherapeutic approaches in ovarian cancer. Results: Standard treatment for ovarian cancer includes cytoreductive surgery followed by platinum-based chemotherapy; however, recurrence and platinum resistance remain major clinical challenges. In recent years, immunotherapy has emerged as an actively investigated treatment strategy, particularly in platinum-resistant disease. Various strategies are under investigation, including immune checkpoint inhibitors, CAR T-cell therapies, and oncolytic viruses. PD-1/PD-L1 inhibitors have shown potential efficacy, especially in tumors expressing PD-L1, which may serve as a predictive biomarker for treatment response. Conclusions: Despite promising research results, the clinical benefits of immunotherapy in ovarian cancer remain limited. Future studies should focus on identifying reliable predictive biomarkers, optimizing combination therapies, and improving treatment efficacy while maintaining an acceptable safety profile.

• Details
• Contents